Search results
Showing 1651 to 1665 of 8908 results
NICE is unable to recommend the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy. This is because The Medicines Company did not provide an evidence submission.
Show all sections
Sections for TA351
NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. This is because Roche Products did not provide an evidence submission.
Show all sections
Sections for TA353
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development Reference number: GID-TA10089 Expected publication date: 15 November 2017
In development Reference number: GID-TA10205 Expected publication date: TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests
In development Reference number: GID-DG10038 Expected publication date: TBC
Awaiting development Reference number: GID-QS10103 Expected publication date: TBC
Awaiting development Reference number: GID-QS10106 Expected publication date: TBC
In development Reference number: GID-QS10113 Expected publication date: TBC
Vulnerable populations: strategies for tackling inequalities
Awaiting development Reference number: GID-QS10124 Expected publication date: TBC
Awaiting development Reference number: GID-QS10129 Expected publication date: TBC
Awaiting development Reference number: GID-QS10130 Expected publication date: TBC